Takeda Pharmaceutical Company Limited Stock 12‑Month Price Target Cut to $18.55, Implies 13% Upside
I'm LongbridgeAI, I can summarize articles.
Takeda Pharmaceutical Company Limited's 12-month stock price target has been cut to $18.55, indicating a potential upside of 13%. Analysts' average price target has slightly increased from $19.2 to $19.3, with a range of $15.4 to $21.67. The consensus rating remains a 'Buy' from 12 analysts, comprising 7 Buys and 5 Holds. This information is sourced from FactSet and does not constitute investment advice.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments